Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
Effectiveness and safety of PCSK9 inhibitors in children with family hypercholesterolemia
https://doi.org/10.33667/2078-5631-2024-13-74-80
Abstract
Familial hypercholesterolemia (CGHS) is a monogenic disease with a predominantly autosomal dominant type of inheritance, accompanied by a significant increase in the level of low-density lipoprotein cholesterol in the blood, and as a result, premature development and progressive course of atherosclerosis, usually at a young age. One of the common causes of the disease is a mutation in the PCSK9 gene. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the main link in the regulation of blood lipid metabolism due to its direct participation in the degradation of LDL receptors. Currently, only evolocumab is used as PCSK9 inhibitors in children over 12 years of age in the Russian Federation, which has proven the safety and steady reduction of LDL cholesterol in pediatric patients with HES. Another representative of this pharmacological group is alirocumab, which is currently indicated only for people over the age of 18, due to the lack of evidence in children.
About the Authors
R. A. Khachaturyan
Novosibirsk State Medical University
Russian Federation
Russian Federation
Khidirova Lyudmila D. - DM Sci (habil.), professor of the Dept of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine.
Novosibirsk
L. D. Khidirova
Novosibirsk State Medical University
Russian Federation
Russian Federation
Khachaturyan Ruslan A. - 6th year student of the pediatric faculty.
Novosibirsk
A. E. Karavozova
Novosibirsk State Medical University
Russian Federation
Russian Federation
Karavozova Anastasia E. - 6th year student of the pediatric faculty.
Novosibirsk
References
1. Defesche J. C., Gidding S. S., Harada-Shiba M. et al. Familial hypercholesterolaemia. Nat. Rev. Dis. Primers. 2017 Dec 7; 3: 17093. DOI: 10.1038/nrdp.2017.93. PMID: 29219151.
2. Akioyamen L. E., Genest J., Shan S. D. et al. Estimating the preva- lence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open. 2017; 7 (9): e016461.
3. Wiegman A., Gidding S. S., Watts G. F. et al. European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. European heart journal. 2015; 36 (36): 2425–2437. https://doi.org/10.1093/eurheartj/ehv157
4. Yezhov M. V. et al. Clinical recommendations for familial hypercholesterolemia. Atherosclerosis. 2019; 15(1): 58–98. (In Russ.)
5. Luirink I. K., Wiegman A., Kusters D. M. et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. The New England Journal of medicine. 2019; 381(16): 1547–1556. https://doi.org/10.1056/NEJMoa1816454
6. Maliachova O., Stabouli S. Familial Hypercholesterolemia in Children and Adolescents: Diagnosis and Treatment. Current pharmaceutical design. 2018; 24 (31): 3672–3677. https://doi.org/10.2174/1381612824666181010145807
7. Malyarevskaya O. V. et al. PCSK9 inhibitors: their role in reducing cardiovascular morbidity. South Russian Journal of Therapeutic Practice. 2022; 3 (2): 32–40. (In Russ.)
8. Chaulin A. M., Duplyakov D. V. On the role of PCSK9 in the development of atherosclerosis: molecular aspects. Molecular medicine. 2021; 19 (2): 8–15. (In Russ.)
9. Averkova A. O. PCSK9: regulation of biological activity and the relationship with fat and carbohydrate metabolism. Clinical practice. 2017; 3 (31); 70–75. (In Russ.)
10. Meshkov A. N. et al. PCSK9 levels in families of patients with familial hypercholesterolemia. Atherosclerosis and dyslipidemia. 2012; 1: 12–15. (In Russ.)
11. Santos R. D., Stein E. A., Hovingh G. K. et al. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the American College of Cardiology. 2020; 75 (6): 565–574. https://doi.org/10.1016/j.jacc.2019.12.020
12. Momtazi-Borojeni A.A., Pirro M., Xu S., Sahebkar A. PCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective. Current medicinal chemistry 2020; 29 (6): 980–999. https://doi.org/10.2174/0929867328666211027125245
13. Lan N. S.R., Bajaj A., Watts G. F., Cuchel M. Recent advances in the management and implementation of care for familial hypercholesterolaemia. Pharmacological research, 2023; 194: 106857. https://doi.org/10.1016/j.phrs.2023.106857
14. Smolina M. O. et al. PCSK9: New Victory and Horizons. Ateroscleroz. 2018; 14 (3): 70–77. (In Russ.) https://doi.org/10.15372/ATER2018031115.
15. Konovalov G. A., Bazhan S. S. Evolokumab: innovative possibilities for reducing low-density lipoprotein cholesterol, lipoprotein (a) and cardiovascular risk management. Cardiology: News. Opinions. Training, 2017; 2 (13): 45–56. (In Russ.) DOI: 10.24411/2309–1908–2017–00025
16. Yezhov M. V. et al. Russian recommendations for the diagnosis and treatment of familial hypercholesterolemia. Atherosclerosis and dyslipidemia. 2016; 4.:21–29. (In Russ.)
17. Santos R. D. et al. Evolocumab in pediatric heterozygous familial hypercholesterolemia. New England Journal of Medicine. 2020; 383 (14): 1317–1327.
18. Gaudet D. et al. Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia. Journal of clinical lipidology. 2022; 16 (5): 676–684.
19. Santos R. D. et al. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. The Lancet Diabetes & Endocrinology. 2022; 10 (10): 732–740.
20. Wiegman A. et al. Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia.European Heart Journal. 2022; 43 (2): 544. https://doi.org/10.1093/eurheartj/ehac544.2375
21. Daniels S. et al. Corrigendum to PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS Journal of clinical lipidology. 2020; 14 (5): 741–741.
22. Raal F. J. et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. The Lancet. 2015; 385 (9965): 341–350.
23. Bruckert E. et al. Efficacy and safety of alirocumab in children and adolescents with homozygous familial hypercholesterolemia: phase 3, multinational open-label study. Arteriosclerosis, Thrombosis and Vascular Biology. 2022; 42 (12):1447–1457.
24. Bruckert E. et al. Trial assessing long-term use of PCSK9 inhibition in patients with genetic LDL disorders (TAUSSIG): Efficacy and safety in patients with homozygous familial hypercholesterolemia receiving lipid apheresis. Circulation. 2014; 130 (2): A17016-A17016. https://trialbulletin.com/lib/entry/ct-01624142
25. Bansal S. et al. Evolocumab in patients with homozygous familial hypercholesterolemia in India. Journal of Clinical Lipidology. 2021; 15 (6): 814–821. DOI: 10.1016/j.jacl.2021.10.003
Review
For citations:
Khachaturyan R.A., Khidirova L.D., Karavozova A.E. Effectiveness and safety of PCSK9 inhibitors in children with family hypercholesterolemia. Medical alphabet. 2024;(13):74-80. (In Russ.) https://doi.org/10.33667/2078-5631-2024-13-74-80
Views:
473
Email this article 